Mystic Pharmaceuticals Receives Multiple U.S. Patent Office Notices of Allowance on Drug Delivery Platform Technologies

Published: Sep 17, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced today it has received two Notices of Allowance from the U.S. Patent Office for its “Unit Dose Drug Delivery Platform” (serial number 12/851,524) and Piercing Device for Drug Delivery Systems (serial number 13/149,584) patent applications. These patents expand Mystic’s novel VersiDoser® and VRx2™ delivery platforms enabling the development of patient-centric pharmaceutical products. Mystic is applying its innovative delivery technology to develop therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases affecting large global populations.

Help employers find you! Check out all the jobs and post your resume.

Back to news